Masimo Corporation (MASI)
| Market Cap | 9.34B +6.4% |
| Revenue (ttm) | 1.56B +9.2% |
| Net Income | 76.30M |
| EPS | 1.42 |
| Shares Out | 52.37M |
| PE Ratio | 44.14 |
| Forward PE | 29.38 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 757,754 |
| Open | 178.58 |
| Previous Close | 178.50 |
| Day's Range | 178.26 - 178.58 |
| 52-Week Range | 125.94 - 179.00 |
| Beta | 1.13 |
| Analysts | Hold |
| Price Target | 184.00 (+3.19%) |
| Earnings Date | May 22, 2026 |
About MASI
Masimo Corporation engages in the development, manufacture, and marketing of various patient monitoring technologies, and automation and connectivity solutions worldwide. It offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo Rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of oxygen, carboxyhemoglobin, and methemoglobin. It also pro... [Read more]
Financial Performance
In fiscal year 2025, Masimo's revenue was $1.53 billion, an increase of 9.44% compared to the previous year's $1.40 billion. Losses were -$151.50 million, -50.31% less than in 2024.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for MASI stock is "Hold." The 12-month stock price target is $184.0, which is an increase of 3.19% from the latest price.
News
Masimo shareholders approve acquisition by Danaher
Masimo (MASI) announced that its stockholders voted in favor of the proposal to adopt the previously announced Agreement and Plan of Merger, dated February 16, 2026, by and among Masimo,
Masimo Shareholders Approve Acquisition by Danaher
IRVINE, Calif.--(BUSINESS WIRE)--Masimo Corporation (Nasdaq: MASI) (“Masimo”), a leading global innovator in patient monitoring, today announced that its stockholders voted in favor of the proposal to...
Masimo Transcript: EGM 2026
Shareholders approved the merger with Danaher and a related executive compensation proposal. The CEO highlighted strategic achievements and the benefits of joining Danaher, with Masimo to operate independently within its diagnostics sector.
Masimo announces findings of study of accuracy of Masimo SET pulse oximetry
Masimo (MASI) announced the findings of a study evaluating the accuracy of Masimo SET pulse oximetry among critically ill neonates and demonstrating less than 1% overall statistical bias. Importantly,...
Masimo SET® Pulse Oximetry Performed Accurately on Hospitalized Newborns of All Skin Tones in Largest-Ever Prospective Real-World Study
IRVINE, Calif.--(BUSINESS WIRE)-- #Masimo--A NICU study evaluating Masimo SET® pulse oximetry on hospitalized newborns found no clinically significant differences in accuracy across skin tones.
Masimo awarded $100M Defense Logistics Agency contract modification
Masimo (MASI) has been awarded a maximum $100M modification exercising the five-year option period of a five-year base contract with one five-year option period for patient monitoring and capital equi...
Masimo downgraded to Market Perform from Outperform at Raymond James
Raymond James downgraded Masimo (MASI) to Market Perform from Outperform without a price target The firm expects the announced acquisition by Danaher (DHR) to close in Q2 or Q3 with
Early ruling says Apple Watch redesign not infringing patents, Bloomberg reports
A redesigned Apple Watch doesn’t infringe two Masimo (MASI) patents, a U.S. trade judge found in an early win for Apple (AAPL) that could allow imports of the device if
Judge approves Apple Watch redesign in Masimo patent case, Bloomberg says
11:17 EDT Judge approves Apple (AAPL) Watch redesign in Masimo (MASI) patent case, Bloomberg says
Masimo assumed with an Equal Weight at Wells Fargo
Wells Fargo assumed coverage of Masimo (MASI) with an Equal Weight rating and $180 price target The firm is maintaining the current rating, price target and estimates. Published first on
Halper Sadeh LLC is Investigating Whether KW and MASI are Obtaining Fair Deals for their Shareholders
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.
Halper Sadeh LLC is Investigating Whether MASI and KW are Obtaining Fair Deals for their Shareholders
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.
What's Happening With Masimo Stock?
Masimo stock (MASI) has faced a challenging year, trailing the broader market with a -3% annual return. While shares surged 34% yesterday following news of an acquisition by Danaher, this spike only p...
Masimo moved to No Rating at BofA
BofA moved from Neutral to No Rating on Masimo (MASI) after Danaher (DHR) agreed to acquire the company for a total consideration of $9.9B, or $180 per share. Published first
Masimo downgraded to Neutral from Buy at BTIG
BTIG analyst Marie Thibault downgraded Masimo (MASI) to Neutral from Buy following the announcement that Danaher (DHR) entered a definitive agreement to acquire the company for $180/share in cash. BTI...
Masimo downgraded to Hold from Buy at Stifel
Stifel downgraded Masimo (MASI) to Hold from Buy with an $180 price target after the company agreed to be acquired by Danaher (DHR) for about $9.9B, or $180 per share.
Masimo downgraded to Neutral from Overweight at Piper Sandler
Piper Sandler analyst Jason Bednar downgraded Masimo (MASI) to Neutral from Overweight with a price target of $180, down from $210, after the company entered into an agreement pursuant to
Morning Movers: Masimo surges, Danaher slumps after $9.9B deal
Stock futures are generally trading lower, reflecting renewed concerns about artificial intelligence-related disruption after last week’s weakness in tech and software stocks. Markets are broadly soft...
Masimo to be acquired by Danaher for $180.00 per share in cash
Masimo (MASI) announced that it has entered into a definitive agreement pursuant to which Danaher (DHR) will acquire Masimo for $180.00 per share in cash, representing a total consideration of
Danaher to acquire Masimo for $180 per share in cash, or $9.9B
08:00 EST Danaher (DHR) to acquire Masimo (MASI) for $180 per share in cash, or $9.9B
Danaher to acquire Masimo for $180 per share in cash, or $9.9B
Danaher (DHR) announced that it has entered into a definitive agreement to acquire Masimo (MASI). Under the terms of the agreement, Danaher will acquire all of the outstanding shares of
Danaher to buy Masimo for $9.9 billion
Danaher will acquire pulse oximeter maker Masimo for $9.9 billion, the company said on Tuesday, as the contract research firm looks to bulk up its diagnostics portfolio.
Masimo to be Acquired by Danaher for $180.00 Per Share
IRVINE, Calif.--(BUSINESS WIRE)--Masimo Corporation (Nasdaq: MASI) (“Masimo”), a leading global medical innovator, today announced that it has entered into a definitive agreement pursuant to which Dan...